<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cure CMD</title>
	<atom:link href="http://curecmd.org/feed" rel="self" type="application/rss+xml" />
	<link>http://curecmd.org</link>
	<description>Cure CMD provides Congenital Muscular Dystrophy resources, information, and support to families, doctors, and researchers.</description>
	<lastBuildDate>Fri, 19 Mar 2010 08:00:00 +0000</lastBuildDate>
	
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Trophos Completes Patient Enrolment In Pivotal Phase 3 Efficacy Study Of Olesoxime In Amyotrophic Lateral Sclerosis (Lou Gehrig&#8217;s Disease)</title>
		<link>http://mnt.to/f/3z8M</link>
		<comments>http://mnt.to/f/3z8M#comments</comments>
		<pubDate>Fri, 19 Mar 2010 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3z8M</guid>
		<description><![CDATA[Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500 patients recruited into the pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS)...]]></description>
			<content:encoded><![CDATA[Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500 patients recruited into the pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS)...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3z8M/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ALS Therapy Development Institute And Aestus Therapeutics, Inc. Collaborate To Investigate Potential Treatments For ALS</title>
		<link>http://mnt.to/f/3z6H</link>
		<comments>http://mnt.to/f/3z6H#comments</comments>
		<pubDate>Thu, 18 Mar 2010 11:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3z6H</guid>
		<description><![CDATA[The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).       "Aestus is a key, strategic drug discovery partner in the effort to identify potential therapeutics for ALS...]]></description>
			<content:encoded><![CDATA[The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).       "Aestus is a key, strategic drug discovery partner in the effort to identify potential therapeutics for ALS...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3z6H/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SMA Research: Saving Shortened SMN Protein</title>
		<link>http://quest.mda.org/news/sma-research-saving-shortened-smn-protein</link>
		<comments>http://quest.mda.org/news/sma-research-saving-shortened-smn-protein#comments</comments>
		<pubDate>Thu, 18 Mar 2010 03:18:41 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">tag:www.mda.org://44724cadc2b45cb99563afa97fdf2ee0</guid>
		<description><![CDATA[Preserving a shortened version of the SMN protein rescued SMN-deficient cells, opening the door to a possible new therapeutic strategy]]></description>
			<content:encoded><![CDATA[Preserving a shortened version of the SMN protein rescued SMN-deficient cells, opening the door to a possible new therapeutic strategy]]></content:encoded>
			<wfw:commentRss>http://quest.mda.org/news/sma-research-saving-shortened-smn-protein/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Opening New Avenue For Developing Treatments For Genetic Muscle-Wasting Disease</title>
		<link>http://mnt.to/f/3z29</link>
		<comments>http://mnt.to/f/3z29#comments</comments>
		<pubDate>Wed, 17 Mar 2010 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3z29</guid>
		<description><![CDATA[Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr...]]></description>
			<content:encoded><![CDATA[Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3z29/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Discovery Of Chemical That May Protect Hearts Of Muscular Dystrophy Patients</title>
		<link>http://mnt.to/f/3yYd</link>
		<comments>http://mnt.to/f/3yYd#comments</comments>
		<pubDate>Tue, 16 Mar 2010 11:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3yYd</guid>
		<description><![CDATA[Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children. The chemical, which Medical School scientists have termed a "molecular band-aid," seeks out tiny cuts in diseased heart muscle...]]></description>
			<content:encoded><![CDATA[Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children. The chemical, which Medical School scientists have termed a "molecular band-aid," seeks out tiny cuts in diseased heart muscle...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3yYd/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Army Of New Care Advisors Joins The Fight Against Muscle Disease, UK</title>
		<link>http://mnt.to/f/3ySL</link>
		<comments>http://mnt.to/f/3ySL#comments</comments>
		<pubDate>Sun, 14 Mar 2010 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3ySL</guid>
		<description><![CDATA[An army of 19 new and newly secured care advisors will be joining the fight against muscle disease across the UK with the Muscular Dystrophy Campaign...]]></description>
			<content:encoded><![CDATA[An army of 19 new and newly secured care advisors will be joining the fight against muscle disease across the UK with the Muscular Dystrophy Campaign...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3ySL/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diary Note: East Of England Muscle Disease Conference</title>
		<link>http://mnt.to/f/3yNB</link>
		<comments>http://mnt.to/f/3yNB#comments</comments>
		<pubDate>Thu, 11 Mar 2010 14:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3yNB</guid>
		<description><![CDATA[What Families living with muscle disease in the East of England are joining forces with clinicians and MPs at an inaugural conference for the region, organised by the Muscular Dystrophy Campaign.  The conference will be an opportunity for families to learn more about fighting for better muscle disease services in their region and to find out how local campaigning can make a real difference...]]></description>
			<content:encoded><![CDATA[What Families living with muscle disease in the East of England are joining forces with clinicians and MPs at an inaugural conference for the region, organised by the Muscular Dystrophy Campaign.  The conference will be an opportunity for families to learn more about fighting for better muscle disease services in their region and to find out how local campaigning can make a real difference...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3yNB/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Prenatal Screening For Rare Diseases Like Spinal Muscular Atrophy Too Costly?</title>
		<link>http://mnt.to/f/3yFc</link>
		<comments>http://mnt.to/f/3yFc#comments</comments>
		<pubDate>Tue, 09 Mar 2010 09:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">http://mnt.to/f/3yFc</guid>
		<description><![CDATA[Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis...]]></description>
			<content:encoded><![CDATA[Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis...]]></content:encoded>
			<wfw:commentRss>http://mnt.to/f/3yFc/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ALS TDI: Full Speed Ahead</title>
		<link>http://quest.mda.org/news/als-tdi-full-speed-ahead</link>
		<comments>http://quest.mda.org/news/als-tdi-full-speed-ahead#comments</comments>
		<pubDate>Tue, 09 Mar 2010 01:23:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">tag:www.mda.org://6dae51579364ea5e6e6159dd8aeed8c4</guid>
		<description><![CDATA[ALS TDI's first-quarter 2010 research update can be summed up with one word: momentum.]]></description>
			<content:encoded><![CDATA[ALS TDI's first-quarter 2010 research update can be summed up with one word: momentum.]]></content:encoded>
			<wfw:commentRss>http://quest.mda.org/news/als-tdi-full-speed-ahead/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gene Therapy Book by MDA Grantee</title>
		<link>http://quest.mda.org/news/gene-therapy-book-mda-grantee</link>
		<comments>http://quest.mda.org/news/gene-therapy-book-mda-grantee#comments</comments>
		<pubDate>Tue, 09 Mar 2010 01:23:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News from Other Sources]]></category>

		<guid isPermaLink="false">tag:www.mda.org://95a3a51f8168dbc4857416906d43b8b1</guid>
		<description><![CDATA['Muscle Gene Therapy' brings together the latest research in this promising field.]]></description>
			<content:encoded><![CDATA['Muscle Gene Therapy' brings together the latest research in this promising field.]]></content:encoded>
			<wfw:commentRss>http://quest.mda.org/news/gene-therapy-book-mda-grantee/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
